Literature DB >> 12890634

Characterization of IgA response among women with incident HPV 16 infection.

Takashi Onda1, Joseph J Carter, Laura A Koutsky, James P Hughes, Shu-Kuang Lee, Jane Kuypers, Nancy Kiviat, Denise A Galloway.   

Abstract

Previous studies have characterized the prevalence and duration of serum IgG antibodies to human papillomavirus type 16 (HPV 16) in a well-studied cohort of college women, using viruslike particle- (VLP) based ELISAs. In this study IgA antibodies in cervical secretions and sera were examined using a newly developed capsomer-based ELISA and the patterns observed for serum IgG, serum IgA, and cervical IgA antibodies were compared. The median time to antibody detection from the first detection of HPV 16 DNA was 10.5 months for IgA in cervical secretions and 19.1 months for serum IgA. Serum IgA antibody conversion was observed less frequently and occurred later than IgA conversion in cervical secretions (P = 0.011) or serum IgG conversion (P = 0.051). The median time to antibody reversion, following seroconversion, was 12.0 months for IgA in cervical secretions and 13.6 months for serum IgA, whereas approximately 20% of women with serum IgG antibodies reverted within 36 months. Thus, the duration of IgA in cervical secretions and sera was shorter than the duration of serum IgG (P = 0.007 and 0.001).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890634     DOI: 10.1016/s0042-6822(03)00196-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.

Authors:  Johnnie J Orozco; Joseph J Carter; Laura A Koutsky; Denise A Galloway
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Authors:  Dianne J Marais; Debbie Constant; Bruce Allan; Henri Carrara; Margaret Hoffman; Samuel Shapiro; Chelsea Morroni; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

3.  Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.

Authors:  Sepideh Farhat; Mayumi Nakagawa; Anna-Barbara Moscicki
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

4.  Association of antibody to E2 protein of human papillomavirus and p16INK4A with progression of HPV-infected cervical lesions.

Authors:  Jureeporn Chuerduangphui; Chamsai Pientong; Piyawut Swangphon; Sanguanchoke Luanratanakorn; Ussanee Sangkomkamhang; Thumwadee Tungsiriwattana; Pilaiwan Kleebkaow; Ati Burassakarn; Tipaya Ekalaksananan
Journal:  Med Oncol       Date:  2018-05-09       Impact factor: 3.064

Review 5.  Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

Authors:  Maria Lina Tornesello; Luigi Buonaguro; Paolo Giorgi-Rossi; Franco M Buonaguro
Journal:  Biomed Res Int       Date:  2013-12-09       Impact factor: 3.411

6.  Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia.

Authors:  Nataša Vasiljević; Paul D Carter; Caroline Reuter; Rhian Warman; Adam R Brentnall; James R Carton; Jack Cuzick; Attila T Lorincz
Journal:  Int J Cancer       Date:  2017-06-01       Impact factor: 7.396

Review 7.  Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature.

Authors:  Jade Pattyn; Severien Van Keer; Wiebren Tjalma; Veerle Matheeussen; Pierre Van Damme; Alex Vorsters
Journal:  Papillomavirus Res       Date:  2019-09-05

8.  Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.

Authors:  S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.